Precision Medicine for the Heart
Unlocking the power of DNA to identify, manage, and prevent cardiovascular diseases through advanced Cardiac Genomics and Pharmacogenomics (PGx).
What is Cardio Genomics?
Cardio Genomics is the clinical study of how an individual's unique genetic makeup impacts their cardiovascular health, risk for inherited heart diseases, and response to cardiac treatments.
Heart disease is often thought to be primarily driven by lifestyle and environmental factors. However, genomics plays a fundamental role. Inherited cardiovascular conditions are often elusive until a severe event occurs. Unlocking this genomic information is critical for early detection, familial screening, and tailored therapy.
Quick Facts: Cardio Genomics & PGx
Cardio genomics: analyzes inherited genetic mutations linked to heart conditions, sudden cardiac arrest, and cardiomyopathies.
Cardio PGx: determines how your DNA affects your response to heart medications (e.g., Clopidogrel, Statins, Warfarin).
Diagnostic & Preventive: Actionable insights to tailor treatment plans and prevent hospital readmissions.
Personalized: No two hearts are the same; your genetics guide your personalized cardiology care.
The Four Pillars of Cardiac DNA Testing
Cardiac Gene Study (Risk Profiling)
Our comprehensive cardiac gene panels sequence dozens of genes associated with inherited structural and electrical heart conditions (over 100 genes). This identifies risk factors for conditions like Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).
Cardio PGx (Pharmacogenomics)
Not all heart medications work the same for everyone. A standard dose can save one life but cause severe side effects in another due to genetic variations. Cardio PGx profiling helps physicians prescribe the right medication at the right dose for drugs like Warfarin, Clopidogrel, Statins, and Beta Blockers, minimizing adverse drug reactions.
Diagnostic Importance
When a patient presents with symptoms that are ambiguous or have a mixed clinical picture, genetic sequencing acts as the definitive diagnostic tool. It moves cardiology from a symptom-based reactive approach to a definitive, molecular-level diagnosis, allowing targeted therapies based on the genetic root cause.
Preventive Importance (Cascade Testing)
If a specific genetic mutation is found in a patient (the "proband"), it is highly recommended to screen their close relatives (cascade testing). Because these inherited diseases are usually autosomal dominant, family members have a 50% chance of carrying the same mutation and can take preventive action.
A genomic-first approach transitions cardiovascular care from reactive, generalized models to proactive, personalized models of care that improve patient outcomes.
Comparison
| Aspect | Traditional Cardiology | Genomic Cardiology | |
|---|---|---|---|
| Approach | Reactive (Treating symptoms as they appear) | Proactive and Predictive (Determining risk before symptoms occur) | |
| Medication Prescribing | Trial and error (Standard dose for all) | Cardio PGx (Patient-DNA-drug matching for precise dose and reduced ADEs) | |
| Family Risk Assessment | Based solely on self-reported family history | Definitive DNA cascade testing for relatives | |
| Diagnostic Certainty | Often clinical; imaging and phenotypic observation | Definitive molecular diagnosis uncovering the genetic etiology |